Sign up Australia
Proactive Investors - Run By Investors For Investors

Immuron enrols first patient in paediatric fatty liver trial in the U.S.

Pediatric NAFLD is a progressive form of liver disease.
Immuron enrols first patient in paediatric fatty liver trial in the U.S.
The trial is designed to assess Immuron’s unique treatment

Immuron (ASX:IMC) has enrolled the first patient for its paediatric NAFLD (non-alcoholic fatty liver disease) Phase II trial conducted by Emory University in Georgia, U.S.

This Phase II, double blind, randomized study is designed to assess the safety and efficacy of Immuron’s IMM-124E for the treatment of paediatric NAFLD.

Paediatric NAFLD is a progressive form of liver disease associated with excessive fat storage in the liver together with inflammation, which can then lead to liver fibrosis and cirrhosis.

IMM-124E works upstream, and on several pathways, to reduce liver inflammation and is a unique treatment option compared to other leading investigational agents.

The principal objective of this study is to evaluate whether 12 weeks of IMM-124E treatment in children with confirmed NALFD will decrease serum ALT.

The study aims to enrol 40 paediatric patients.

Paediatric NAFLD is believed to affect up to 5% - 10% of the U.S. paediatric population.

A U.S. landmark study that examined the incidence of the disease in 742 children found that 17.3% of children aged 15 to 19 years had NAFLD.

There are currently no treatments approved for paediatric NAFLD.

Immuron’s share price has increased about 11% since the start of 2017, last trading at $0.30.

View full IMC profile View Profile

Immuron Ltd Timeline

Newswire
June 08 2017
Newswire
May 30 2017
Newswire
May 27 2016

Related Articles

cancer cell
February 01 2018
The highlights included successful US and European ovarian cancer studies that underlined the potential of the company’s Parsortix liquid biopsy system
Picture of evolis products
April 04 2018
Fillerina® is complementary to the company’s evolis® haircare range.
mri scanner
January 31 2018
It is actively supporting the hunt for breakthrough treatments for Alzheimer’s, Parkinson’s, Huntingdon’s and multiple sclerosis

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use